Viravaxx

News

  • Viravaxx submits Hepatitis B abstract to AASLD

    Vienna, June 17, 2021. Viravaxx’ ongoing phase II clinical trial (NCT03625934) investigates if vaccination with VVX001 can induce a preS-specific antibody response in vaccine naïve adults and in patients chronically infected with HBV. In the trial, 4 cohorts are enrolled in a prospective double-blind, placebo-controlled clinical study. Cohort 1: vaccine naïve subjects; cohort 2: subjects | read more »

    read more »

  • SARS-CoV-2 Vaccine Candidate to Induce Sterilizing Immunity

    Vienna, April 22, 2021. Viravaxx’ SARS-CoV-2 blocking Antibody Test informs if a COVID-19 convalescent patient or vaccinated person has developed neutralizing antibodies which block the interaction of RBD with ACE2. Viravaxx used its proprietary SARS-CoV-2 blocking Antibody Test to analyze serum samples from patients who recovered from COVID-19. The findings helped to understand the requirements | read more »

    read more »

  • With new appointment, Viravaxx aims to step up a gear

    Vienna, Jan 11, 2021. Austrian antiviral vaccine and immunodiagnostics specialist Viravaxx has appointed Helmut Brunar, former CEO and chairman at Axentis Pharma, as chief executive officer. Dr Brunar has broad experience in vaccines and cell therapies, having managed supply chain activities at Johnson & Johnson’s (NYSE: JNJ) COVID-19 vaccine program. In his eleven years as CEO | read more »

    read more »

  • Seven different “disease forms” identified in mild COVID-19

    Vienna, Nov 2, 2020. In a study recently published in the top journal “Allergy”, a team of MedUni Vienna scientists led by immunologist Winfried F. Pickl and allergologist Rudolf Valenta (both from the Center for Pathophysiology, Infectiology and Immunology) showed that there are seven “forms of disease” in COVID-19 with mild disease course and that the | read more »

    read more »

  • COVID-19: not all patients develop protective antibodies

    Vienna, Aug 5, 2020: A laboratory test that has now been developed by a study group from MedUni Vienna is able to determine whether COVID-19 patients develop protective antibodies after having the disease. The main finding of the test is as follows: the scientists from MedUni Vienna’s Institute of Pathophysiology and Allergy Research discovered that | read more »

    read more »

  • Viravaxx AG and the Medical University of Vienna develop an integrated platform for immune diagnosis and vaccination for COVID-19

    Vienna, April 9, 2020:  Viravaxx and the Medical University of Vienna develop an integrated platform for immune diagnosis and vaccination of Covid-19. Based on our novel Si/SiO2 microchip technology platform, a microarray is created, on which  the structural proteins of the SARS-CoV-2 virus in glycosylated and non-glycosylated form are represented as well as certain relevant fragments of | read more »

    read more »

  • Landmark paper on Viravaxx’ rhinovirus diagnostic tool published in Nature Communications

    Vienna, July 4, 2018: Viravaxx announced today that a Landmark paper describing the utility of its multiplexed diagnostic chip for analysis of the immune response to a rhinovirus infection in children has been published in the high impact Journal Nature Communications. The following is a comment in “Behind the Paper” published in Nature Research Community Microbiology, a forum for | read more »

    read more »